62results about How to "Dosing is simple" patented technology

A device for dosing and forming pods (1) containing a product for infusion and comprising a piece of filter material containing a dose of the product for infusion. The device comprises: a station (2) for feeding the product into at least one forming impression (3) defining a single dose of the product and made in means (4) for forming a respective compressed disk (5) of the infusion product and releasing the compressed disk (5) from the impression (3) in the filter material to form the pod (1).

Dosing components (22, 24, 32) in an engine exhaust after-treatment system (18) that includes an SCR catalyst (20) are thermally managed by flowing engine coolant through a coolant passage in a urea injector (22) that injects aqueous urea into the after-treatment system, controlling a three-way valve (60) to selectively direct coolant flow leaving the urea injector to a first branch that is in heat exchange relationship with a tank (24) that holds a supply of aqueous urea and a supply pump module (32) that pumps aqueous urea from the tank to the urea injector, and a second branch that is not in heat exchange relationship with either the tank or the supply pump, and returning coolant from the branches to the engine cooling system.

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and / or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

A flocculation-electroheterogeneous catalysis method for treating naphthenic acid wastewater. First, air flotation-flocculation treatment is carried out on naphthenic acid wastewater, the pressure is 0.2-0.4MPa, and the dosage of the agent is 0.01-0.07% of the wastewater volume; after the flocculation treatment, the DC voltage between the electrodes in the electric field is 5-15V, and the current Under an external electric field of 200-400 mA per square decimeter, the organic pollutants in the naphthenic acid wastewater are catalyzed and oxidized on the surface of the catalyst. The experimental results show that the combined technology can be used to treat naphthenic acid wastewater, which can be directly discharged up to the standard, and the operating cost is low.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

An apparatus is proposed for the dosed dispensing of a fluid, especially an infusion fluid, comprising a housing (1) with a fluid chamber and a pressure medium chamber (3) by which a flexible wall (4) of the fluid chamber can be pressurized from the outside with a pressure medium. In order to provide a re-useable infusion pump with especially simple means it is proposed that the housing (1) consists of two mutually detachably joined housing parts (6, 7), of which the one comprises the pressure medium chamber (3) and the other receives in an exchangeable manner the fluid chamber configured as a leak-proof infusion bag (2), and that the housing part (6) with the pressure medium chamber (3) is sealed by a membrane (5) against the housing part (7) receiving the infusion bag (2) and is connected to a gas pressure source (11).

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

The invention provides a household sewage treatment device of a circulating fluidized bed.The household sewage treatment device comprises an anaerobic reaction unit, an aerobic reaction unit and a filtering and precipitating unit.A water inlet is formed in the upper portion of the anaerobic reaction unit, and a stirring air pipe is arranged at the bottom of the anaerobic reaction unit.The aerobic reaction unit is filled with efficient biocompatibility filler.A filter material bearing plate is arranged at the lower portion of the filtering and precipitating unit, and a cover plate is arranged at the upper portion of the filtering and precipitating unit.The space between the filter material bearing plate and the cover plate is filled with a filter material.A water outlet is formed in the upper portion of the filtering and precipitating unit, and the bottom of the anaerobic reaction unit is communicated with the upper area of the filler cover plate of the aerobic reaction unit through a first connecting pipe.The bottom of the aerobic reaction unit is communicated with the lower area of the filter material bearing plate through a second communicating pipe.The upper portion of the anaerobic reaction unit is communicated with the lower area of the filter material bearing plate through a backflow pipe.The household sewage treatment device has the advantages of being high in sewage treatment efficiency, small in occupied area, capable of easily making the sewage treatment result to reach the standards and the like.

The invention relates to a removal method for 2-phosphomobutane-1,2,4-tricarboxylic acid in organophosphorus-containing wastewater.The method comprises the steps that calcium hydroxide, ferric salt or aluminum salt and a flocculant solution are sequentially added into the wastewater containing organophosphorus 2-phosphomobutane-1,2,4-tricarboxylic acid, the removal rate of organophosphorus 2-phosphomobutane-1,2,4-tricarboxylic acid can reach 89% or above, and the concentration of phosphorus in the solution can be lowered to 0.5 mg / L or below.The method is easy and convenient to operate, low in cost and stable in operation, the total phosphorus concentration of effluent can be controlled to be in a low level, and the total phosphorus discharge standard of the effluent is met.

The invention provides a preparation method for environment-friendly nanometer emulsion fracturing fluid. The method comprises the following steps of dissolving monomers A, monomers B, monomers C, inorganic salts and dispersing agents into deionized water to form a mixed solution; performing heating and nitrogen gas introduction; adding initiators to initiate the polymerization under the nitrogen gas protection; meanwhile, dispersing the mixed solution by using high-speed dispersion combining high-pressure homogenizing or high-pressure microjet to form dispersing liquid; diluting the dispersing liquid so as to obtain the environment-friendly nanometer emulsion fracturing fluid through preparation. The monomers A are water-soluble monomers with carbon-carbon double bonds; the monomers B are cationoid water-soluble monomers with carbon-carbon double bonds; the monomers C are polyether type monomers with carbon-carbon double bonds. The preparation method for the fracturing fluid is simple; the environment-friendly effect and no pollution are realized; the energy consumption is low; the application range is wide; meanwhile, the excellent functions of resistance reduction, clay stability, discharge assistance, sand suspending, surface activity reduction and the like are realized; high stability is realized; layering flocculation, accumulation and sedimentation cannot easily occur.

The invention relates to a method for treating waste water containing multiple mixed organophosphorus scale and corrosion inhibitors.Calcium hydroxide, ferrous sulfate and a flocculating agent solution are sequentially added to the waste water containing ATMP, HEDP and / or PBTCA organophosphorus scale and corrosion inhibitors, the organophosphorus removal rate effect can reach 95% or above, and the phosphorus concentration in the solution can be reduced to 0.2 mg / L or below.According to the method, the chemical reagents are directly added to remove organophosphorus ATMP, HEDP and PBCA, operation is easy and convenient, cost is low, the total phosphorus concentration of effluent can be controlled at a low level, and the effluent total phosphorus emission standard is met.

The present invention relates to industrial effluent treating technology, and is especially one kind of comprehensive cutting effluent treating technological method. The technological process includes the first air floatation-flocculation treatment in pressure of 0.2-0.4 MPa and flocculant consumption of 0.1-6 wt% of the effluent; subsequent ultrafiltration-reverse osmosis treatment including two-stage of microfilm filtering at 0.05-0.6 MPa and reverse osmosis at 0.5-1.5 MPa; and final electrical multiphase catalytic oxidation in the voltage 10-15 V and current density of 100-400 mA / sq dm and in the presence of supported catalyst with Fe or Mn oxide as the active component and in the amount of 1 / 5 to 5 / 6 of effluent volume. The present invention has the advantages of high effluent treating effect resulting in capacity of direct exhaust, low treatment cost, simple operation and no secondary pollution.